A

Adaptimmune Therapeutics plc

D
ADAP
USD
-0.02
(-1.9417%)
Market Closed
26,492.00
Volume
-0.80502
EPS
-
Div Yield
-2.805556
P/E
258,302,899.45
Market Cap
Today
-1.9417%
1 Week
-8.597%
1 Month
-9.821%
6 Months
-27.338%
12 Months
38.091%
Year To Date
27.800%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
C
CRSP
-0.11
(-0.2219%)
USD
E
EDIT
0.05
(1.292%)
USD
S
SGMO
0.0617
(7.3584%)
USD
N
NTLA
0.41
(1.8214%)
USD
R
RGNX
-0.043
(-0.3429%)
USD
F
FIXX
(%)
USD
V
VYGR
0.07
(1.1236%)
USD

Title:
Adaptimmune Therapeutics plc

Sector:
Healthcare
Industry:
Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Do you need help or have a question?
Contact Us